Which deals accidentally brought in the biggest biopharma blockbusters? A new analysis by Vantage reveals all.
The latest venture capital numbers suggest that 2019 will see a healthy amount raised, but the falling number of rounds could be a worry.
Amgen’s AMG 510 disappoints Kras bulls, showing just two new partial responses, in colorectal and appendiceal tumours.
As J&J tears up a licensing deal with Alligator, CD40 agonism might join the likes of Ox40 and IDO as an immuno-oncology approach that has failed to deliver.
Celgene opts out of Jounce’s Icos agonist ahead of its merger with Bristol-Myers Squibb.
Neon's cancer vaccine makes a decent early showing, but overall survival remain a crucial measure.
Neon Therapeutics is due to unveil the first rigorous test of its neoantigen approach to fighting tumours, while Neurotrope makes a brave bid in Alzheimer's.
Sangamo is slowly building a case for SB-525 over Biomarin’s valrox.
Turning Point is heading into a highly competitive lung cancer niche with its lead project, which still has much to prove.